A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer

Gemcitabine (GEM)-based chemotherapy is regarded as the standard treatment of pancreatic adenocarcinoma, but yields a very limited disease control. Very few studies have investigated salvage chemotherapy after failure of GEM or GEM-containing chemotherapy and preclinical studies attempting to widen...

Descripción completa

Detalles Bibliográficos
Autores principales: Mercalli, A, Sordi, V, Formicola, R, Dandrea, M, Beghelli, S, Scarpa, A, Di Carlo, V, Reni, M, Piemonti, L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360188/
https://www.ncbi.nlm.nih.gov/pubmed/17426706
http://dx.doi.org/10.1038/sj.bjc.6603726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360188/
https://www.ncbi.nlm.nih.gov/pubmed/17426706
http://dx.doi.org/10.1038/sj.bjc.6603726

Ejemplares similares